Drug intelligence / Profile preview

CM512

Development stage: Phase 3
Lead developer: Keymed Biosciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous Injection

Overview

CM512 is a bispecific antibody developed by Keymed Biosciences that targets both interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). It acts as an immunomodulator, modulating the activity of these cytokines involved in type 2 inflammation. The drug is being investigated for several inflammatory and allergic diseases, including atopic dermatitis, chronic rhinosinusitis with nasal polyps, asthma, chronic bronchitis, and chronic obstructive pulmonary disease. Its mechanism of action involves dual inhibition of IL-13 and TSLP pathways to reduce inflammation associated with these conditions[1][8].

Other names: CM 512CM512CM-512

Targets

IL-13 (Interleukin-13)TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on CM512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM512.

Explore the full profile